Top Tech Companies (124)
Don't see your company?
Create a company profile
Let's transform lives together and work towards a functional, confident smile on every face
Enara Bio is shining a light on Dark Antigen® and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients. Our pioneering EDAPT® platform enables us to discover novel cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing database of Dark Antigens that can address the unmet need for cancer-specific targets that are homogenously expressed and highly prevalent in solid tumors. We are advancing multiple approaches to exploit these Dark Antigen targets, with an internal focus on TCR-directed immunotherapies, and additional therapeutic partnerships with Boehringer Ingelheim and another undisclosed global pharmaceutical company. Based in Oxford, UK, Enara Bio is backed by RA Capital, Samsara Biocapital and SV Health Investors. For more information, please visit: www.enarabio.com Comments and DMs to this account are not monitored, for any further information please head to our website
We believe that everyone - irrespective of who they are or where they live - deserve medications that work
Ori Biotech is a London- and New Jersey-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalised, lifesaving treatments. By fully automating and standardising CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing. So complex manufacturing challenges can be put where they belong – in the past
Phytoform are making agriculture sustainable & unlocking the genetic potential of plants.
LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases
At Opvia, we empower R&D, manufacturing and quality management teams to build custom process operating systems that streamline their workflows and give them a competitive edge. We work with fast-growing startups and enterprises across a range of industries, including biotech, pharma, food and beverages, engineering and medical devices, to help them digitize their processes and bring innovative products to market faster. With our powerful tools and expert support, we give companies the freedom to create and deliver like never before.
FabricNano is a biotechnology company based in London. Our mission is to transform industrial chemical processes using cell-free biomanufacturing. Empowering users with the world’s most advanced, flexible and easily-scalable biocatalyst platform. We develop and sell biocatalysts for high volume industrial applications. Data-driven in our approach to enzyme and Immobilization Engineering™, we only use biocatalyst materials that can already be manufactured by the tonne. Our clients range from startups to international chemical clients like Sumitomo Chemical Company, all of which are looking for highly stable and performant biocatalysts to enable profitable production of sustainable and bio-based chemicals. The FabricNano offer starts with novel Immobilization Engineering™ for enzyme stabilization, followed by budget-conscious protein engineering and process engineering to reach the client’s targets for commercialization of the new biochemical production process.
ENBIOSIS Biosciences reaches deep into your inner world with microbiome analysis and offers you the key for a sustainable and healthy life
Personalised cancer therapeutics platform pioneered at Mount Sinai Medical Center
Shellworks is a design-led techbio company that creates uncompromising, compostable packaging solutions made from naturally-derived materials. Our first material is called Vivomer, a bio-based, vegan and home compostable alternative to plastic. Working in collaboration with nature, Vivomer is made and unmade by microbes
We are an RNA delivery and therapeutics company. Our proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon. Our Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improve the stability, safety, and transfection efficiency of RNA. We use sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and are maximizing the potential of our technology through research partnerships. Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, we have fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate
Atlas Biomed is a personalized health company applying the latest genetic technologies to inspire consumers into a positive lifestyle change, and lead them into a healthier future.
Causaly amplifies human cognitive abilities to expand the boundaries of discovery towards making the best decisions in Biomedicine. To achieve this, we are teaching computers to read all knowledge ever published and develop an interface that allows humans to answer questions they can’t ask anywhere else.
The way we see it, the impossible is not impossible. It’s simply what hasn’t been achieved yet. For more than 30 years, we’ve pursued it, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases. Creating Possible drives everything we do. It’s evident in our mission and core values. This is how we built a culture of excellence that is fueled by a passion for improving lives of people around the world. For us, nothing is impossible – because of the people we work with, the communities we stand with and the partners we push forward with. Our ~12,000 employees band together through science, grit, compassion and courage to prove the impossible wrong. At Gilead, the tangible results of your contributions are evident. Where every individual matters. Where all employees can enhance their skills through ongoing development. And where we start every day with one question: “What’s next?” Social Media Guidelines: https://gilead.inc/3t1m7d5
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from high-resolution biology, machine learning and clinical insights. Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select druggable targets and develop transformational medicines.
Copilot for clinical trials. Trained on over 700,000 clinical trials, patents and publications, neuroute Copilot turns natural language prompts into clinical development support to bring medications to patients sooner. Use Copilot to conduct market analysis, feasibility, design your clinical trial, select and review sites, find physician champions, generate documents (protocols, statistical analysis plans, SOPs), fix your enrollment, and more. Let Copilot do the manual work for you so you can focus on innovation
We transform green waste into a leather-like material that is low-resource, recyclable, and compostable.
Valink Therapeutics (formerly LiliumX) is a spinout of the University of Oxford, focused on the development of next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating bi-/multispecificity, multivalency and drug-conjugation into a single discovery process via our Universal Assembly Platform™. Our internal research focus is on solid tumours poorly addressed by immunotherapy, in addition to select platform collaborations
